Eclipta (Eclipta alba), commonly known as false daisy, has a long history of use in traditional Ayurvedic and Chinese medicine to support liver health. In Ayurveda, it is called "Bhringraj" and is traditionally considered a "rasayana" herb, believed to rejuvenate and protect the liver.

From a scientific perspective, several preclinical (animal and in vitro) studies have investigated Eclipta's effect on the hepatic system. Research indicates that extracts of Eclipta alba possess hepatoprotective properties, primarily attributed to bioactive compounds such as wedelolactone, ecliptine, and flavonoids. These compounds have demonstrated the ability to protect liver cells from damage induced by toxins such as carbon tetrachloride, paracetamol, and alcohol in animal models. The mechanisms proposed for these effects include antioxidant activity, enhancement of hepatic glutathione levels, and reduction of lipid peroxidation.

While these findings are promising, it is important to note that most of the evidence comes from laboratory and animal studies. There are very few human clinical trials evaluating the efficacy of Eclipta for liver support, and the existing ones are limited in scale and methodological quality. As such, while scientific research does provide some validation for Eclipta's use in supporting the hepatic system, stronger clinical evidence is needed before it can be conclusively recommended for this purpose in humans.